Skip to main content

Mercedes Arrúe Gonzalo

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Mercedes Arrúe Gonzalo

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

PhD in Neuroscience (2018-2022)
Master in Pharmacological research (2017-2018)
Degree in Biology (2007-2013)

Projects

Validació funcional d’una nova teràpia intravenosa de reemplaçament enzimàtic per a malalties lisosomals amb afectació sistèmica i cerebral

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Pablo Castillo Sánchez, Jordi Riera del Brío
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 148830
Reference: SLT041/25/000039
Duration: 04/12/2025 - 03/12/2027

Advancing Parkinson's disease management: targeting autophagic-lysosomal dysfunction for innovative diagnostics and therapeutics

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Pablo Castillo Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 265000
Reference: PI24/00062
Duration: 01/01/2025 - 31/12/2027

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/09/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 01/07/2027

Related news

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

The event focused on advances in disease-modifying therapies and on the value of alliances between patients and professionals to promote more participatory care and research.

This VHIR initiative promotes well-being, empathy and community participation in Barcelona neighbourhoods through an intergenerational model

Related professionals

Mariana Perez Cano

Mariana Perez Cano

Research technician
Translational Molecular Pathology
Read more
Marc Montoursi Picas

Marc Montoursi Picas

Predoctoral researcher
Protein kinases in cancer research
Read more
Núria Cuéllar Baqué

Núria Cuéllar Baqué

Main researcher
Multidisciplinary Nursing Research Group
Read more
Melania López Romero

Melania López Romero

Fundraising Unit
Communication Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.